Treatment Strategy and Perioperative Risk in Patients with Idiopathic Thrombocytopenic Purpura Undergoing Cardiac Surgery

Patients suffering from idiopathic thrombocytopenic purpura undergoing cardiac surgery with extracorporeal circulation may be at increased risk for postoperative bleeding complications. Therefore, different treatment strategies, such as conservative treatment, splenectomy, transfusion of platelet concentrates and therapy with immunoglobulins have been proposed. We report on our experiences with preoperative immunoglobulin treatment in selected patients with special regard on the optimal dosage.

Key words:

Idiopathic thrombocytopenic purpura - Cardiac surgery - Perioperative risk - Immunoglobulin treatment

References

• 1 Christiansen S, Schmid C, Redmann K. et al . Preoperative immunoglobulin treatment in patients with Werlhof's disease undergoing cardiac operation.  Ann Thorac Surg. 2000;  69 61-64
• 2 Christiansen S, Rötker J, Roeder N. et al . Are patients with Werlhof’s disease at increased risk for bleeding complications when undergoing cardiac surgery?.  Eur J Cardiothorac Surg. 2000;  18 353-356
• 3 George J N, Woolf S H, Raskob G E. et al . Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology.  Blood. 1996;  88 3-40
• 4 Keon W J, Sherrard H. Early release following cardiac surgery.  Current Opinion in Cardiology. 1996;  11 599-602
• 5 Mathew T C, Vasudevan R, Leb L, Pezella S M, Pezella A T. Coronary artery bypass grafting in immune thrombocytopenic purpura.  Ann Thorac Surg. 1997;  64 1059-1062
• 6 Berchtold P, Wenger M. Autoantibodies Against Platelet Glycoproteins in Autoimmune Thrombocytopenic Purpura: Their Clinical Significance and Response to Treatment.  Blood. 1993;  81 1246-1250